Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0277787 (
stigma
)
13,352
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Optimal pharmacologic management of pain requires selection of the appropriate analgesic drug, prescription of the appropriate dose, administration of the analgesic by the appropriate route, scheduling of the appropriate dosing interval, prevention of persistent pain and relief of breakthrough pain, aggressive titration of the dose of the analgesic, prevention, anticipation, and management of analgesic side-effects, use of appropriate co-analgesic drugs, and consideration of sequential trials of opioid analgesics. Controlled-release oxycodone (CRO) has the characteristics of an 'ideal' opioid analgesic drug: short half-life, long duration of action, predictable pharmacokinetics, absence of clinically active metabolites, rapid onset of action, easy titration, no ceiling dose, minimal adverse effects, and minimal associated
stigma
. CRO has been shown to be effective in the control of pain caused by cancer, osteoarthritis,
post-herpetic neuralgia
, major surgery, and degenerative spine disease.
...
PMID:Advancement of opioid analgesia with controlled-release oxycodone. 1179 30
A significant proportion of patients with skin diseases have associated psychosocial factors. Not only does psychopathology manifest on the skin in absence of any real skin disease, primary skin disorders can also be exacerbated by emotional stress adversely influencing the homeostasis of immunological and inflammatory processes in deeper layers of the skin. Furthermore, many patients develop emotional problems as a result of having disfiguring skin diseases. In addition, some patients having solely sensory disturbances in absence of primary dermatoses or identifiable medical or neurological conditions, as well as some purely dermatologic conditions such as
post-herpetic neuralgia
may preferentially need psychotherapeutic modalities to address their underlying psychopathology irrespective of the presenting dermatologic manifestation arising out of 'somatisation' of a psychopathology into physical problems. The most obvious course of action of referral to a psychiatrist or another mental health professional may unfortunately not be readily tenable either due to the perceived
stigma
associated with psychiatric illness or lack of insight on the part of patients. In the interregnum, effective management of the psychologic or/and psychiatric problems can only be done by the dermatologist provided he has an adequate knowledge base and experience to undertake psychotherapeutic modalities.
...
PMID:Skin and Psyche : Diversionary Symbiosis. 2740 40